Bio-Works Technologies
Bio-Works reports first quarter 2024
MAR
Today, Bio-Works Technologies announced net sales for the first quarter amounted to 6.1 MSEK, a 20% decrease versus the same period in 2023.
The first quarter in review
- Order intake amounted to 6.2 MSEK, a 44% decrease versus the same period in 2023.
- Order backlog at the end of the period amounted to 4.6 MSEK.
- Operating expenses (excluding raw materials) amounted to 17.1 MSEK, in-line with the company’s operating plan estimate for the first quarter.
“Order intake has been much weaker expected during the first quarter of the year. We continue to focus all our efforts to improve sales effectiveness. At the same time we are looking for avenues to capitalize our technology platform in segments outside our current reach” stated Jonathan Royce, CEO for Bio-Works.
Datum | 2024-04-22, kl 09:15 |
Källa | MFN |
![](https://static.allaaktier.se/ads/hand-waving-2.png)